Gallia Levy, MD, PhD

Gallia Levy, MD, PhD, joined Kite in 2024 as Senior Vice President and Global Head of Clinical Development.

Prior to joining Kite, Gallia was the Chief Medical and Product Strategy Officer at Spark Therapeutics, a part of the Roche Group. As a member of the Corporate Management Team, she led the global development and product strategy for Spark’s portfolio of genetic therapies. Before Spark, Gallia was Vice President and Global Head of the Rare Blood Disorders Franchise in Product Development at Genentech/Roche, where she was responsible for the global clinical development of treatments for hemophilia A and other rare blood disorders.

Gallia is board-certified in hematology and earned an MD and PhD in Molecular and Cellular Biology from the University of Michigan, during which time discovered ADAMTS13, responsible for Thrombotic Thrombocytopenic Purpura (TTP). She completed her residency in internal medicine at Stanford University and a fellowship in hematology at the University of California, San Francisco. She also spent time at the Pasteur Institute during which she received an M.S. in Molecular and Cellular Biology from the University of Paris, VI. She holds a bachelor’s degree from the University of California, Berkeley.